WIN Consortium

Recent papers from WIN Consortium

1. Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and bloodiScience · 2026
2. OptiRanker: a simulation and optimization framework for efficient in vivo validation of drug prioritization algorithmsScientific Reports · 2026
3. Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer TreatmentJCO Precision Oncology · 2026
4. PD-L2 Landscape and Correlation With Outcome: An Immunomic AnalysisJCO oncology advances. · 2026
5. Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)Clinical Cancer Research · 2025
6. Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy CombinationsJCO Precision Oncology · 2025
7. OptiRanker: an Advanced Tool for Simulation and Comparative Analysis of Drug Prioritization Algorithms in in-Vivo Trials2025
8. Designing Clinical Trials for Patients With Rare Cancers: Connecting the ZebrasAmerican Society of Clinical Oncology Educational Book · 2025
9. ICOS and ICOS ligand: expression patterns and outcomes in oncology patientsTherapeutic Advances in Medical Oncology · 2025
10. The Molecular Tumor Board Turns 10: The Age of ComplexityThe Oncologist · 2024
11. Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumorsBJC Reports · 2024
12. Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategyiScience · 2024
13. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in CancerInternational Journal of Molecular Sciences · 2024
14. If it’s a target, it’s a pan-cancer target: Tissue is not the issueCancer Treatment Reviews · 2024
15. Viewing the immune checkpoint VISTA: landscape and outcomes across cancersESMO Open · 2024
16. Images in Immunotherapy and Precision Oncology: Advanced Basal Cell CarcinomaJournal of Immunotherapy and Precision Oncology · 2024
17. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCLCancer Treatment Reviews · 2024
18. Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1Journal of Immunotherapy and Precision Oncology · 2024
19. Critical insights into the evolving drug‐approval process in ChinaCancer · 2024
20. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcomeTherapeutic Advances in Medical Oncology · 2024